Handelen Pluri Inc. - PLUR CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.0424 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 1.0088 |
Open* | 1.0188 |
1-Jaarlijkse Verandering* | -42.11% |
Dagelijks bereik* | 1.0188 - 1.0488 |
52 wekelijks bereik | 0.65-2.21 |
Weekgemiddelde volume (10 dagen) | 31.83K |
Gemiddeld volume (3 maanden) | 1.46M |
Marktkapitalisatie | 35.27M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 32.66M |
Omzet | 321.00K |
EPS | -1.12 |
Dividend (opbrengst %) | N/A |
Beta | 1.60 |
Volgende inkomsten datum | N/A |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 1.0088 | -0.0400 | -3.81% | 1.0488 | 1.0488 | 1.0088 |
Feb 6, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0288 | 1.0088 |
Feb 3, 2023 | 1.0587 | -0.0600 | -5.36% | 1.1187 | 1.1287 | 1.0587 |
Feb 2, 2023 | 1.1187 | 0.0200 | 1.82% | 1.0987 | 1.1187 | 1.0787 |
Jan 27, 2023 | 1.1187 | -0.0299 | -2.60% | 1.1486 | 1.1586 | 1.1087 |
Jan 26, 2023 | 1.1287 | 0.0100 | 0.89% | 1.1187 | 1.1287 | 1.1187 |
Jan 25, 2023 | 1.0887 | 0.0000 | 0.00% | 1.0887 | 1.0887 | 1.0887 |
Jan 24, 2023 | 1.1586 | 0.0000 | 0.00% | 1.1586 | 1.1686 | 1.1586 |
Jan 20, 2023 | 1.1586 | -0.0400 | -3.34% | 1.1986 | 1.1986 | 1.1586 |
Jan 19, 2023 | 1.2286 | 0.0200 | 1.65% | 1.2086 | 1.2585 | 1.1686 |
Jan 18, 2023 | 1.2785 | 0.0599 | 4.92% | 1.2186 | 1.2785 | 1.2186 |
Jan 17, 2023 | 1.2585 | 0.0799 | 6.78% | 1.1786 | 1.3285 | 1.1786 |
Jan 13, 2023 | 1.2086 | 0.1399 | 13.09% | 1.0687 | 1.3984 | 1.0687 |
Jan 12, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0687 | 1.0288 |
Jan 11, 2023 | 1.0088 | -0.0200 | -1.94% | 1.0288 | 1.0288 | 1.0088 |
Jan 9, 2023 | 1.0288 | 0.0300 | 3.00% | 0.9988 | 1.0588 | 0.9988 |
Jan 6, 2023 | 0.9986 | 0.0435 | 4.55% | 0.9551 | 1.0288 | 0.9551 |
Jan 5, 2023 | 0.9550 | -0.0299 | -3.04% | 0.9849 | 0.9850 | 0.9489 |
Jan 4, 2023 | 0.9987 | 0.0039 | 0.39% | 0.9948 | 0.9988 | 0.9948 |
Jan 3, 2023 | 0.9916 | 0.0067 | 0.68% | 0.9849 | 0.9985 | 0.9788 |
Pluri Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale inkomsten | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Inkomsten | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Kosten van opbrengsten, totaal | 0.1 | 0 | 0.002 | 0.002 | 0 | 0 |
Brutowinst | 2.747 | 0 | 0.048 | 0.052 | 0.023 | 0 |
Totale bedrijfskosten | 26.166 | 28.019 | 33.781 | 35.586 | 29.499 | 50.623 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 6.486 | 6.927 | 11.193 | 9.157 | 7.922 | 20.557 |
Onderzoek & Ontwikkeling | 20.85 | 21.972 | 24.478 | 12.841 | 21.643 | 13.47 |
Depreciation / Amortization | 2.006 | 2.029 | 1.893 | 1.841 | 1.453 | 1.252 |
Other Operating Expenses, Total | -3.276 | -2.909 | -3.785 | 11.745 | -1.519 | 15.344 |
Bedrijfsresultaat | -23.319 | -28.019 | -33.731 | -35.532 | -29.476 | -50.623 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.109 | 0.272 | 8.542 | 0.105 | 0.356 | 0.781 |
Overige, Netto | -0.036 | -0.067 | -0.937 | 0.12 | -0.032 | -0.023 |
Netto inkomen voor belastingen | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Netto inkomen na belastingen | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Netto inkomen voor extra. Posten | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Netto inkomen | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Verwaterd Netto Inkomen | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Verwaterd Gewogen Gemiddelde Aandelen | 7.9548 | 8.74262 | 10.5877 | 1.23329 | 18.1973 | 28.1136 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.92226 | -3.18143 | -2.46759 | -28.6283 | -1.602 | -1.77369 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Verwaterde Genormaliseerde Winst per Aandeel | -2.85237 | -3.12149 | -2.38995 | -28.1158 | -1.5688 | -1.74709 |
Q3 2021 | Q4 2021 | Q1 2021 | Q2 2021 | Q3 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 0 | 0 | 0 | 0 | 0.234 |
Inkomsten | 0 | 0 | 0.234 | ||
Kosten van opbrengsten, totaal | 0 | 0 | |||
Brutowinst | 0 | 0 | |||
Totale bedrijfskosten | 14.225 | 14.587 | 11.441 | 10.795 | 10.709 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 6.559 | 6.102 | 5.088 | 4.288 | 4.553 |
Onderzoek & Ontwikkeling | 7.824 | 8.507 | 6.391 | 6.541 | 6.273 |
Other Operating Expenses, Total | -0.158 | -0.022 | -0.038 | -0.034 | -0.117 |
Bedrijfsresultaat | -14.225 | -14.587 | -11.441 | -10.795 | -10.475 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.029 | 0.019 | 0.009 | -0.145 | 0.557 |
Netto inkomen voor belastingen | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Netto inkomen na belastingen | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Netto inkomen voor extra. Posten | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Netto inkomen | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Verwaterd Netto Inkomen | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Verwaterd Gewogen Gemiddelde Aandelen | 29.6172 | 31.6441 | 32.0008 | 32.1363 | 32.2616 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totaal vlottende activa | 35.596 | 29.016 | 32.036 | 26.371 | 48.461 | 67.371 |
Geldmiddelen en kortetermijnbeleggingen | 32.208 | 26.106 | 29.9 | 23.705 | 45.784 | 64.95 |
Geldmiddelen & Equivalenten | 6.223 | 4.707 | 8.821 | 4.106 | 8.27 | 31.241 |
Korte Termijn Investeringen | 25.985 | 21.399 | 21.079 | 19.599 | 37.514 | 33.709 |
Totale Vorderingen, Netto | 2.481 | 1.174 | 0.847 | 1.421 | 1.61 | 1.49 |
Accounts Receivable - Trade, Net | 2.251 | 1.036 | 0.69 | 1.243 | 1.248 | 1.108 |
Prepaid Expenses | 0.3 | 0.882 | 0.602 | 0.532 | 0.445 | 0.333 |
Other Current Assets, Total | 0.607 | 0.854 | 0.687 | 0.713 | 0.622 | 0.598 |
Total Assets | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Property/Plant/Equipment, Total - Net | 9.216 | 7.277 | 5.678 | 3.838 | 3.775 | 2.227 |
Property/Plant/Equipment, Total - Gross | 17.183 | 16.507 | 16.893 | 17.004 | 18.437 | 18.259 |
Accumulated Depreciation, Total | -7.967 | -9.23 | -11.215 | -13.166 | -14.662 | -16.032 |
Long Term Investments | 0.363 | 0.403 | 0.383 | 0.398 | 12.653 | 23.269 |
Other Long Term Assets, Total | 0.766 | 0.838 | 0.863 | 0.703 | 0.643 | 0.671 |
Total Current Liabilities | 5.775 | 5.414 | 8.548 | 8.158 | 7.987 | 11.517 |
Accounts Payable | 2.705 | 1.966 | 3.261 | 2.281 | 1.968 | 2.526 |
Accrued Expenses | 2.819 | 3.106 | 4.164 | 5.637 | 5.893 | 8.951 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.251 | 0.342 | 1.123 | 0.24 | 0.126 | 0.04 |
Total Liabilities | 7.785 | 7.283 | 10.453 | 9.489 | 9.431 | 36.387 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 23.85 |
Other Liabilities, Total | 2.01 | 1.869 | 1.905 | 1.331 | 1.444 | 1.02 |
Total Equity | 38.156 | 30.251 | 28.507 | 21.821 | 56.101 | 57.151 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | ||
Additional Paid-In Capital | 198.432 | 217.822 | 244.203 | 272.824 | 336.257 | 387.172 |
Retained Earnings (Accumulated Deficit) | -161.757 | -189.571 | -215.697 | -251.004 | -280.156 | -330.021 |
Unrealized Gain (Loss) | 1.48 | 1.48 | 8.44 | |||
Other Equity, Total | 0 | 0.519 | -8.44 | |||
Total Liabilities & Shareholders’ Equity | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Total Common Shares Outstanding | 8.0269 | 9.69388 | 11.3566 | 15.0829 | 25.4927 | 31.9578 |
Long Term Debt | 23.85 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 49.82 | 67.371 | 62.826 | 60.153 | 64.313 |
Geldmiddelen en kortetermijnbeleggingen | 47.37 | 64.95 | 60.671 | 58.183 | 61.98 |
Geldmiddelen & Equivalenten | 12.265 | 31.241 | 14.611 | 18.715 | 23.791 |
Korte Termijn Investeringen | 35.105 | 33.709 | 46.06 | 39.468 | 38.189 |
Other Current Assets, Total | 2.45 | 2.421 | 2.155 | 1.97 | 2.333 |
Total Assets | 79.174 | 93.538 | 83.747 | 81.184 | 79.127 |
Property/Plant/Equipment, Total - Net | 2.713 | 2.227 | 1.749 | 9.331 | 9.14 |
Long Term Investments | 25.937 | 23.269 | 18.483 | 10.965 | 4.235 |
Other Long Term Assets, Total | 0.704 | 0.671 | 0.689 | 0.735 | 1.439 |
Total Current Liabilities | 9.916 | 11.517 | 10.365 | 9.595 | 7.822 |
Accounts Payable | 2.11 | 2.526 | 3.723 | 4.058 | 3.942 |
Accrued Expenses | 5.613 | 6.575 | 6.642 | 5.537 | 3.88 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.193 | 2.416 | |||
Total Liabilities | 11.038 | 36.387 | 34.84 | 41.344 | 41.034 |
Total Long Term Debt | 0 | 23.85 | 23.444 | 23.158 | 22.924 |
Other Liabilities, Total | 1.122 | 1.02 | 1.031 | 8.591 | 8.238 |
Total Equity | 68.136 | 57.151 | 48.907 | 39.84 | 38.0933 |
Additional Paid-In Capital | 383.589 | 387.172 | 390.36 | 392.233 | 400.351 |
Retained Earnings (Accumulated Deficit) | -315.453 | -330.021 | -341.453 | -352.393 | -362.258 |
Total Liabilities & Shareholders’ Equity | 79.174 | 93.538 | 83.747 | 81.184 | 79.1273 |
Total Common Shares Outstanding | 31.7402 | 31.9578 | 32.0969 | 32.2251 | 32.3424 |
Totale Vorderingen, Netto | 0 | ||||
Accounts Receivable - Trade, Net | 0 | ||||
Current Port. of LT Debt/Capital Leases | 0 | ||||
Long Term Debt | 23.85 | 23.444 | 23.158 | 22.924 | |
Common Stock | 0.00032 | 0.00032 | |||
Other Equity, Total | -0.00032 | ||||
Minority Interest | 2.05 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Geldmiddelen uit Operationele Activiteiten | -18.522 | -21.611 | -21.38 | -29.453 | -26.369 | -30.91 |
Geldmiddelen uit Operationele Activiteiten | 2.15 | 2.177 | 2.018 | 1.962 | 1.57 | 1.37 |
Niet-Geldelijke Posten | 3.498 | 4.174 | -1.025 | 5.146 | 2.562 | 13.968 |
Cash Taxes Paid | 0.066 | 0.028 | 0.027 | 0.01 | 0.01 | |
Veranderingen in het Operationeel Kapitaal | -0.924 | -0.148 | 3.753 | -1.254 | -1.349 | 3.617 |
Geldmiddelen uit Investeringsactiviteiten | 1.312 | 4.355 | 5.681 | 1.17 | -30.458 | -7.265 |
Kapitaaluitgaven | -1.75 | -0.378 | -0.342 | -0.239 | -0.27 | -0.373 |
Overige Cash Flow investeringsposten, Totaal | 3.062 | 4.733 | 6.023 | 1.409 | -30.188 | -6.892 |
Geldmiddelen uit Financieringsactiviteiten | 0.807 | 15.797 | 19.921 | 23.582 | 60.87 | 61.402 |
Uitgifte (Aflossing) van aandelen, netto | 0.807 | 15.728 | 19.833 | 23.475 | 60.87 | 36.953 |
Nettowijziging in Geldmiddelen | -16.403 | -1.459 | 4.222 | -4.701 | 4.043 | 22.609 |
Financiering van Cash Flow Posten | 0.069 | 0.088 | 0.107 | 0 | ||
Uitgifte (Aflossing) van Schulden, Netto | 24.449 | |||||
Wisselkoerseffecten | -0.618 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -35.297 | -49.865 | -11.432 | -22.372 | -32.29 |
Cash From Operating Activities | -21.313 | -30.91 | -8.789 | -18.652 | -28.074 |
Cash From Operating Activities | 1.034 | 1.37 | 0.337 | 0.664 | 0.915 |
Non-Cash Items | 10.382 | 13.968 | 3.188 | 6.1 | 7.782 |
Cash Taxes Paid | 0.008 | ||||
Changes in Working Capital | 2.568 | 3.617 | -0.882 | -3.044 | -4.481 |
Cash From Investing Activities | -12.057 | -7.265 | -7.24 | 7.075 | 14.738 |
Capital Expenditures | -0.331 | -0.373 | -0.015 | -0.044 | -0.081 |
Other Investing Cash Flow Items, Total | -11.726 | -6.892 | -7.225 | 7.119 | 14.819 |
Cash From Financing Activities | 36.992 | 61.402 | 0 | 0 | 7.5 |
Issuance (Retirement) of Stock, Net | 36.992 | 36.953 | 0 | 0 | 0 |
Net Change in Cash | 3.622 | 22.609 | -16.62 | -12.616 | -6.908 |
Issuance (Retirement) of Debt, Net | 24.449 | ||||
Foreign Exchange Effects | -0.618 | -0.591 | -1.039 | -1.072 | |
Financing Cash Flow Items | 7.5 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Yanay (Yaky) | Individual Investor | 3.2937 | 1075620 | 396790 | 2022-12-22 | LOW |
Regals Capital Management, L.P. | Investment Advisor | 3.2824 | 1071938 | 1071938 | 2022-01-24 | |
Aberman (Zalman) | Individual Investor | 2.5434 | 830604 | -2000 | 2022-12-20 | LOW |
Slager (David M) | Individual Investor | 1.8774 | 613100 | 613100 | 2022-01-24 | HIGH |
Nia Impact Capital | Investment Advisor | 0.4071 | 132947 | -318394 | 2022-09-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.3235 | 105657 | -174105 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.3197 | 104400 | -2900 | 2022-09-30 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3142 | 102600 | -10000 | 2022-09-30 | LOW |
Nikko Asset Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.2574 | 84056 | -20865 | 2021-12-31 | LOW |
Franco-Yehuda (Chen) | Individual Investor | 0.225 | 73466 | 6875 | 2022-12-21 | LOW |
Green Alpha Advisors, LLC | Investment Advisor | 0.1794 | 58603 | 2377 | 2022-12-31 | HIGH |
Values First Advisors, Inc. | Investment Advisor | 0.1398 | 45653 | -2677 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1211 | 39544 | 0 | 2022-12-31 | LOW |
Jane Street Capital, L.L.C. | Research Firm | 0.1102 | 35986 | -46524 | 2022-09-30 | HIGH |
Group One Trading, L.P. | Research Firm | 0.0877 | 28638 | -5900 | 2022-09-30 | HIGH |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 0.0842 | 27497 | -137 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0771 | 25169 | 0 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.0625 | 20412 | -120303 | 2022-09-30 | HIGH |
Archford Capital Strategies, LLC | Investment Advisor | 0.0401 | 13091 | 0 | 2022-12-31 | LOW |
Hightower Advisors, LLC | Investment Advisor | 0.0367 | 11985 | -26000 | 2022-09-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com GroupHandelaren
Actieve klanten per maand
Maandelijks beleggingsvolume
Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
Over Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is een ontwikkelaar van placentagebaseerde celtherapie productkandidaten voor de behandeling van meerdere ischemische, inflammatoire en hematologische aandoeningen. De voornaamste indicaties van het bedrijf zijn kritieke ischemie van de ledematen (critical limb ischemia - CLI), herstel na een operatie voor een femurhalsfractuur en acuut stralingssyndroom. De activiteiten van de onderneming zijn gericht op onderzoek, ontwikkeling, klinische proeven en productie van celtherapeutica en verwante technologieën. De producten van het bedrijf omvatten PLX-PAD en PLX R18. De PLX-cellen van het bedrijf zijn adherente stromale cellen (ASC's) die worden geëxpandeerd met behulp van een driedimensionaal (3D) proces. Het systeem maakt gebruik van een synthetische steiger om een kunstmatige 3D-omgeving te creëren waarin van de placenta afgeleide stromale cellen kunnen groeien. De PLX-producten van de Vennootschap worden toegediend met behulp van een standaardnaald en -spuit. De PLX-producten van de Vennootschap bevinden zich in de klinische ontwikkelingsfase voor meerdere indicaties, zoals cardiovasculaire, orthopedische, pulmonale en vrouwenziekten.
Industry: | Biotechnology & Medical Research (NEC) |
MATAM Advanced Technology Park
Building #5
3508409
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen